A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma

Hiroki Saito, Satoshi Ando, Naoya Morishita, Kyung Mi Lee, Dante Dator, David Dy, Katsumi Shigemura, Zainal Adhim, Ken Ichi Nibu, Masato Fujisawa, Toshiro Shirakawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. Materials and Methods: The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Results: Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. Conclusion: The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. Conclusion: The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer.

Original languageEnglish
Pages (from-to)3365-3370
Number of pages6
JournalAnticancer research
Volume34
Issue number7
Publication statusPublished - 2014 Jul 1

Keywords

  • Ad-p53 gene therapy
  • Head neck squamous cell carcinoma
  • LAK immunotherapy
  • TNF-a

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Saito, H., Ando, S., Morishita, N., Lee, K. M., Dator, D., Dy, D., Shigemura, K., Adhim, Z., Nibu, K. I., Fujisawa, M., & Shirakawa, T. (2014). A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. Anticancer research, 34(7), 3365-3370.